About us - IMI AMR Accelerator

The AMR Accelerator

Participants

479

M€ Budget

Projects

Programmes
in the Portfolio

Antibiotic distribution and recovery in tissue

Coordination and support across the AMR Accelerator. Research to strengthen the scientific basis in the AMR field.

Development of anti-TB drug combinations

New antibiotics to treat Gram-negative infections

Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance

Novel assets for non-tuberculous mycobacteria

New assets for multidrug-resistant tuberculosis

Defining a new place for Ethionamide in 1st-line TB treatments

Accelerating the development of new treatment regimens for tuberculosis

Follow us:

The AMR Accelerator has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreements No 853967 I 853989 I 853979 I 853932 I 853800 I 853903 I 853976 I 101007873 I 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB receives additional support from Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.

https://www.imi.europa.eu/